Delivery of tobramycin coupled to iron oxide nanoparticles across the biofilm of mucoidal Pseudonomas aeruginosa and investigation of its efficacy

Armijo, Leisha M.; Kopciuch, Michael; Olszówka, Zuzia; Wawrzyniec, Stephen J.; Rivera, Antonio C.; Plumley, John B.; Cook, Nathaniel C.; Brandt, Yekaterina I.; Huber, Dale L.; Smolyakov, Gennady A.; Adolphi, Natalie L.; Osiński, Marek

doi:10.1117/12.2043340

Cited by 2 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This dry powder formulation has been shown to have a shorter administration time, increased patient adherence and overall satisfaction than TIS [16,17]. Previous studies have shown improved delivery of tobramycin through thick mucus and enhanced treatment of planktonic P. aeruginosa via conjugating its amino groups with carboxyl groups of citric acid-coated magnetic nanoparticles [18,19].…”

Section: Tobramycinmentioning

confidence: 99%

Successes and Challenges: Inhaled Treatment Approaches Using Magnetic Nanoparticles in Cystic Fibrosis

2020

View full text Add to dashboard Cite

Magnetic nanoparticles have been largely applied to increase the efficacy of antibiotics due to passive accumulation provided by enhancing permeability and retention, which is essential for the treatment of lung infections. Recurring lung infections such as in the life-shortening genetic disease cystic fibrosis (CF) are a major problem. The recent advent of the CF modulator drug ivacaftor, alone or in combination with lumacaftor or tezacaftor, has enabled systemic treatment of the majority of patients. Magnetic nanoparticles (MNPs) show unique properties such as biocompatibility and biodegradability as well as magnetic and heat-medicated characteristics. These properties make them suitable to be used as drug carriers and hyperthermia-based agents. Hyperthermia is a promising approach for the thermal activation therapy of several diseases, including pulmonary diseases. The benefits of delivering CF drugs via inhalation using MNPs as drug carriers afford application of sufficient therapeutic dosages directly to the primary target site, while avoiding potential suboptimal pharmacokinetics/pharmacodynamics and minimizing the risks of systemic toxicity. This review explores the multidisciplinary approach of using MNPs as vehicles of drug delivery. Additionally, we highlight advantages such as increased drug concentration at disease site, minimized drug loss and the possibility of specific cell targeting, while addressing major challenges for this emerging field.

show abstract

Section: Tobramycinmentioning

confidence: 99%

Successes and Challenges: Inhaled Treatment Approaches Using Magnetic Nanoparticles in Cystic Fibrosis

2020

View full text Add to dashboard Cite

show abstract

“…Three commonly used antibiotics are tobramycin, aztreonam and colistinmethate sodium. Tobramycin has been shown to improve the eradication of planktonic P. aeruginosa by conjugating with carboxyl groups of citric acid-coated MNPs [31]. Aztreonam is a monocyclic β-lactams antibiotic that is typically used against Gram-negative bacteria by inhibiting cell wall synthesis [32].…”

Section: Current Antibiotic-mnp Treatment Options For Cf Biofilmsmentioning

confidence: 99%

Magnetic Nanoparticle-Based Drug Delivery Approaches for Preventing and Treating Biofilms in Cystic Fibrosis

2020

View full text Add to dashboard Cite

Biofilm-associated infections pose a huge burden on healthcare systems worldwide, with recurrent lung infections occurring due to the persistence of biofilm bacteria populations. In cystic fibrosis (CF), thick viscous mucus acts not only as a physical barrier, but also serves as a nidus for infection. Increased antibiotic resistance in the recent years indicates that current therapeutic strategies aimed at biofilm-associated infections are “failing”, emphasizing the need to develop new and improved drug delivery systems with higher efficacy and efficiency. Magnetic nanoparticles (MNPs) have unique and favourable properties encompassing biocompatibility, biodegradability, magnetic and heat-mediated characteristics, making them suitable drug carriers. Additionally, an external magnetic force can be applied to enhance drug delivery to target sites, acting as “nano-knives”, cutting through the bacterial biofilm layer and characteristically thick mucus in CF. In this review, we explore the multidisciplinary approach of using current and novel MNPs as vehicles of drug delivery. Although many of these offer exciting prospects for future biofilm therapeutics, there are also major challenges of this emerging field that need to be addressed.

show abstract

Delivery of tobramycin coupled to iron oxide nanoparticles across the biofilm of mucoidal Pseudonomas aeruginosa and investigation of its efficacy

Cited by 2 publications

References 31 publications

Successes and Challenges: Inhaled Treatment Approaches Using Magnetic Nanoparticles in Cystic Fibrosis

Successes and Challenges: Inhaled Treatment Approaches Using Magnetic Nanoparticles in Cystic Fibrosis

Magnetic Nanoparticle-Based Drug Delivery Approaches for Preventing and Treating Biofilms in Cystic Fibrosis

Contact Info

Product

Resources

About